189013-61-4Relevant academic research and scientific papers
Evaluation of novel synthetic methods for the preparation of the sodium channel inhibitor, GW273225X
Walker, Matthew D.,Albinson, F. David,Clark, Hugh F.,Clark, Stacy,Henley, Nicholas P.,J. Horan, Richard A.,Jones, Chris W.,Wade, Charles E.,Ward, Richard A.
, p. 82 - 88 (2014/05/20)
The evaluation of efficient synthetic methods for the preparation of (R)-2,4-diamino-5-(2,3-dichlorophenyl)-6- fluoromethylpyrimidine, GW273225X (1), is described. The initial synthesis using ethylfluoroacetate was evaluated against three alternative rout
PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)
-
Page/Page column 48, (2008/12/07)
The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.
Optically active phenyl pyrimidine derivatives as analgesic agent
-
, (2008/06/13)
PCT No. PCT/EP96/03856 Sec. 371 Date Feb. 26, 1998 Sec. 102(e) Date Feb. 26, 1998 PCT Filed Sep. 3, 1996 PCT Pub. No. WO97/09317 PCT Pub. Date Mar. 13, 1997A pyrimidine of formula (I) and its pharmaceutically acceptable acid addition salts are useful as a
